Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» HER2-negative breast cancer
HER2-negative breast cancer
Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients
BioSpace
Mon, 06/6/22 - 11:48 pm
ASCO 2022
Pfizer
Ibrance
HER2-negative breast cancer
ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?
Fierce Pharma
Sun, 06/5/22 - 11:40 pm
ASCO 2022
Pfizer
Ibrance
HR-positive
HER2-negative breast cancer
breast cancer
clinical trials
Pfizer's Ibrance misses shot at big new market with early breast cancer failure
Fierce Pharma
Sun, 05/31/20 - 11:55 pm
Pfizer
Ibrance
ASCO 2020
clinical trials
HER2-negative breast cancer
It May Be Time For Standard Breast Cancer Treatment To Change
Forbes
Sun, 10/6/19 - 12:44 pm
breast cancer
HER2-negative breast cancer
Novartis
ribociclib
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Mon, 06/4/18 - 09:31 am
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
